{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:18:46Z","timestamp":1774462726629,"version":"3.50.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Current research has found contradictory results on the treatment of magnesium valproate (VPM) in patients with dementia (PwD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Here, we conducted a meta-analysis to evaluate the efficacy and safety of VPM in the adjuvant treatment of PwD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Current research has found contradictory results on the treatment of VPM in PwD. Here, we conducted a meta-analysis to evaluate the efficacy and safety of VPM in the adjuvant treatment of PwD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>MEDLINE via PubMed, Cochrane Library, EBSCO, Embase, China National Knowledge (CNKI), and Wan Fang databases were researched to gather relevant data on magnesium valproate assistant therapy for patients with dementia (PwD) by using medical subject headings and term words.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>After the final screening, 22 RCT studies (a total of 1899 participants) were included in this meta-analysis, which compared VPM adjuvant treatment with antidementia or psychotropic drug monotherapy. Significant differences were found in the scores on mini-mental state examination (<jats:italic toggle=\"yes\">P<\/jats:italic> = .028), Alzheimer disease assessment scale cognitive subscale (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05), Bech-Rafaelsen Mania Rating Scale (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05), behavioral pathology in Alzheimer disease rating scale (<jats:italic toggle=\"yes\">P<\/jats:italic> = .001), activities of daily living (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05), and Pittsburgh Sleep Quality Index (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). Besides, the levels of inflammatory factors including IL-1\u03b2, IL-6, and TNF-\u03b1 were significantly lower than those in the monotherapy group (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; .05). While there was no increase in the incidence of adverse events (<jats:italic toggle=\"yes\">P<\/jats:italic> = .383), VPM as an assistant therapy is generally well tolerated in PwD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>By meta-analysis, evidence was found to support VPM additional used for the treatment of cognitive function, psychiatric symptoms, or disease improvement in PwD. VPM may be a potential drug to aid in the treatment of dementia patients. However, there was lack of enough evidence to classification of dementia severity in our inclusion study. More research is still needed, including clinical trials evaluating VPM as a complementary therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000029642","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T14:06:35Z","timestamp":1660053995000},"page":"e29642","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Effects of magnesium valproate adjuvant therapy on patients with dementia: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"101","author":[{"given":"ChenQi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Special-needed Medical, Chengdu BOE Hospital, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LingQi","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Air Force Hospital of Western Theater Command, Chengdu, Sichuan Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HongBin","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sichuan Academy of Medical Sciences and Sichuan, Provincial People\u2019s Hospital, Chengdu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020-2060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the Lancet Commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/alz.12328","article-title":"2021 Alzheimer\u2019s disease facts and figures","volume":"17","year":"2021","journal-title":"Alzheimers Dement"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/0897190011424802","article-title":"Valproic acid in dementia: does an optimal dose exist?","volume":"25","author":"Dolder","year":"2012","journal-title":"J Pharm Pract"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"695315","DOI":"10.3389\/fphar.2021.695315","article-title":"Potentially inappropriate prescriptions of antipsychotics for patients with dementia","volume":"12","author":"Machado-Duque","year":"2021","journal-title":"Front Pharmacol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00002512-200522070-00007","article-title":"Effect of divalproex sodium on behavioural and cognitive problems in elderly dementia","volume":"22","author":"Meinhold","year":"2005","journal-title":"Drugs Aging"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"104091","DOI":"10.1016\/j.archger.2020.104091","article-title":"Efficacy and safety of valproic acid in dementia: a systematic review with meta-analysis","volume":"89","author":"Liu","year":"2020","journal-title":"Arch Gerontol Geriatr"},{"key":"R8-20250504","first-page":"157","article-title":"Seizure susceptibility and mortality in mice that over-express amyloid precursor protein","volume":"1","author":"Westmark","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.braindev.2004.07.008","article-title":"Down syndrome, Alzheimer\u2019s disease and seizures","volume":"27","author":"Men\u00e9ndez","year":"2005","journal-title":"Brain Dev"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/1533317515602674","article-title":"Magnesium status in alzheimer\u2019s disease: a systematic review","volume":"31","author":"Veronese","year":"2016","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1684\/mrh.2011.0287","article-title":"Altered ionized magnesium levels in mild-to-moderate Alzheimer\u2019s disease","volume":"24","author":"Barbagallo","year":"2011","journal-title":"Magnes Res"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"8199","DOI":"10.3390\/nu7095388","article-title":"Magnesium in prevention and therapy","volume":"7","author":"Schmidt","year":"2015","journal-title":"Nutrients"},{"key":"R13-20250504","first-page":"Cd003945","article-title":"Valproate preparations for agitation in dementia","author":"Lonergan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-20250504","first-page":"Cd003945","article-title":"Valproic acid for agitation in dementia","author":"Lonergan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"R15-20250504","first-page":"61","article-title":"Efficacy of magnesium valproate sustained release tablets combined with galanthamine in the treatment of mild to moderate Alzheimer disease","volume":"28","author":"Zhu","year":"2021","journal-title":"Cap Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"e1000100e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"R18-20250504","first-page":"91","article-title":"Efficacy and safety evaluation of Donepezil combined with magnesium valproate in the treatment of Alzheimer\u2019s disease","volume":"21","author":"Su","year":"2021","journal-title":"Pract Clin J Integrated Traditional Chinese Western Med"},{"key":"R19-20250504","first-page":"131","article-title":"Clinical efficacy of magnesium valproate with Donepezil in the treatment of AD patients with mental behavior disorder","volume":"44","author":"Wang","year":"2021","journal-title":"Heilongjiang Med Pharm"},{"key":"R20-20250504","first-page":"90","article-title":"Effect of magnesium valproate sustained release tablets combined with Donepezil hydrochloride tablets on Alzheimer\u2019s disease","volume":"30","author":"Li","year":"2021","journal-title":"Henan Med Res"},{"key":"R21-20250504","first-page":"1212","article-title":"Clinical efficacy analysis of magnesium valproate in adjuvant treatment of senile dementia patients","volume":"32","author":"Zhang","year":"2021","journal-title":"Modern Diagnosis Treat"},{"key":"R22-20250504","first-page":"397","article-title":"Effects of Donepezil combined with magnesium valproate on sleep quality and mental behavior in senile dementia patients","volume":"31","author":"Wei","year":"2020","journal-title":"Modern Diagnosis Treat"},{"key":"R23-20250504","first-page":"699","article-title":"Clinical effect of magnesium valproate combined with donepezil on senile dementia","volume":"15","author":"Wang","year":"2020","journal-title":"China Med"},{"key":"R24-20250504","first-page":"789","article-title":"Effect of magnesium valproate sustained release tablets combined with Donepezil hydrochloride on mental behavior disorder of senile dementia","volume":"31","author":"Bi","year":"2020","journal-title":"J Aerospace Med"},{"key":"R25-20250504","first-page":"303","article-title":"Efficacy of galantamine combined with magnesium valproate in the treatment of Alzheimer\u2019s disease and its effects on serum CER, BDNF and miR-132 levels","volume":"23","author":"Ao","year":"2020","journal-title":"China Pharmacist"},{"key":"R26-20250504","first-page":"95","article-title":"Clinical effect of magnesium valproate combined with Donepezil on senile dementia patients","volume":"5","author":"Zhou","year":"2020","journal-title":"Oriental Medicated Diet"},{"key":"R27-20250504","first-page":"121","article-title":"Effect of magnesium valproate sustained release tablet and Donepezil Hydrochloride capsule on mental behavior disorder of senile dementia","volume":"45","author":"Zhang","year":"2018","journal-title":"Chinese J Pract Med"},{"key":"R28-20250504","first-page":"2069","article-title":"Effect of magnesium valproate combined with donepezil in the treatment of Alzheimer\u2019s cognitive behavior","volume":"41","author":"Liu","year":"2018","journal-title":"Drug Evaluation Res"},{"key":"R29-20250504","first-page":"1025","article-title":"Effect of magnesium valproate combined with donepezil on Alzheimer disease, urine alzheimer-associated neuronal thread protein and plasma lipoprotein-associated phospholipase A2","volume":"13","author":"Cong","year":"2018","journal-title":"China Med"},{"key":"R30-20250504","first-page":"2206","article-title":"Clinical observation of magnesium valproate sustained-release tablets combined with Donepezil Hydrochloride capsules in the treatment of mental and behavioral disorders in senile dementia","volume":"28","author":"Fang","year":"2017","journal-title":"Modern Diagnosis Treat"},{"key":"R31-20250504","first-page":"24","article-title":"A control study of quetiapine plus magnesium valproate sustained-release tablets in behavioral and psychological symptoms of senile dementia","volume":"22","author":"Hao","year":"2016","journal-title":"J Clin Psychosomatic Dis"},{"key":"R32-20250504","first-page":"122","article-title":"Effect of magnesium valproate sustained release tablets combined with olanzapine in the treatment of Alzheimer\u2019s disease","volume":"19","author":"Li","year":"2016","journal-title":"Chinese J Pract Nervous Dis"},{"key":"R33-20250504","first-page":"10","article-title":"The curative effect of magnesium combined with donepezil hydrochloride capsules in the treatment of patients with behavioral and psychiatric disorders in senile dementia","volume":"16","author":"Sun","year":"2016","journal-title":"Medical Information Abstracts"},{"key":"R34-20250504","first-page":"1307","article-title":"Effect of magnesium valproate sustained release tablets combined with olanzapine on Alzheimer\u2019s disease patients","volume":"29","author":"Zhou","year":"2016","journal-title":"J Med Theory Pract"},{"key":"R35-20250504","first-page":"34","article-title":"Clinical observation of magnesium valproate sustained-release tablets combined with Donepezil Hydrochloride capsules in the treatment of mental and behavioral disorders in senile dementia","volume":"20","author":"Fan","year":"2014","journal-title":"J Internal Intensive Med"},{"key":"R36-20250504","first-page":"901","article-title":"Effect of magnesium valproate sustained release tablets combined with olanzapine in the treatment of manic state of Alzheimer\u2019s disease dementia","volume":"38","author":"Zhang","year":"2014","journal-title":"Guizhou Med J"},{"key":"R37-20250504","first-page":"163","article-title":"A controlled study of aripiprazole combined with magnesium valproate in the treatment of mental and behavioral symptoms in patients with Alzheimer\u2019s disease","volume":"23","author":"Yao","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"R38-20250504","first-page":"168","article-title":"Effect of magnesium valproate sustained release tablets combined with olanzapine in the treatment of Alzheimer\u2019s disease with psychiatric and behavioral symptoms","volume":"25","author":"Xie","year":"2012","journal-title":"Sichuan Mental Health"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3389\/fnagi.2019.00062","article-title":"Valproic acid stimulates hippocampal neurogenesis via activating the Wnt\/\u03b2-Catenin signaling pathway in the APP\/PS1\/Nestin-GFP triple transgenic mouse model of Alzheimer\u2019s disease","volume":"11","author":"Zeng","year":"2019","journal-title":"Front Aging Neurosci"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fnagi.2014.00004","article-title":"Dietary mineral intake and risk of mild cognitive impairment: the PATH through life project","volume":"6","author":"Cherbuin","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"R41-20250504","first-page":"Cd003945","article-title":"Valproate preparations for agitation in dementia","volume":"10","author":"Baillon","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"173950","DOI":"10.1016\/j.ejphar.2021.173950","article-title":"A review on \u03b1-mangostin as a potential multi-target-directed ligand for Alzheimer\u2019s disease","volume":"897","author":"Yang","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R43-20250504","first-page":"23","article-title":"Efficacy and side effects of multi-drug treatment on mental and behavioral disorders in patients with Alzheimer\u2019s disease","volume":"5","author":"HY","year":"2017","journal-title":"Cardiovasc Dis J Integrated Traditional Chinese Western Med (Electronic)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:28:43Z","timestamp":1746332923000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000029642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":43,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000029642","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]}}}